Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2008

View Archived Issues

EP4 receptor blocker may be useful in treating chronic arthritis

Mechanisms behind protective effects of KAI-9803 in stroke model determined

Glatiramer and steroid combination treatment beneficial in relapsing-remitting multiple sclerosis

GTx reports results from phase III clinical trial of toremifene citrate 80 mg

Recent Janssen patent discloses antiallergic and antiasthmatic agents

New local anesthetic compounds patented by PharmacoFore

Acambis initiates preclinical testing of dl5-29 HSV-2 vaccine

Bionomics initiates treatment in phase I clinical trial of BNC-105 anticancer drug

CollaGenex signs definitive merger agreement with Galderma

Verona Pharma plans clinical trials of RPL-554 for allergic respiratory diseases

Dr. Falk Pharma initiates phase II clinical study of Dong-A's udenafil for portal hypertension

ADVR signs research agreement with Northeastern University for AVR-118 in cancer

SV2A protein a target in partial and generalized epilepsy

Javelin completes subject accrual in the last of four phase I clinical studies of PMI-150

Health Canada approves Welichem Biotech's CTA for phase IIa clinical trial of WBI-1001

Actelion withdraws application to EMEA for extension of indication for Zavesca

Addex achieves preclinical milestone in agreement with Merck & Co. for allosteric modulators

ImmuPharma initiates dosing in phase IIb trial of IPP-201101 for systemic lupus erythematosus

Osiris reports interim results from phase I trial of Prochymal for myocardial infarction

Synthetic Blood awarded USD 1.9 million grant for phase IIb clinical trial of Oxycyte

Immunosyn reports results from proof-of-concept trial of SF-1019 for diabetic ulcers

VioQuest and the National Cancer Institute enter agreement for Akt inhibitor VQD-002

NPIL commences phase I P-1201-07 trials for metabolic disorders in Europe

FDA issues not approvable letter to Kyowa Hakko for istradefylline in Parkinson's

Novel antithrombotic agents described in recent Fournier and sanofi-aventis patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...